# Abbas-Egbariya et al. Genome Biology (2022) 23:61

# Page 21 of 23

# Acknowledgements

This work was supported by ARC and the Sheba Medical Center support of the Sheba Microbiome Center. YH is also supported by the Israel Science Foundation (908/15), the I‑CORE program (41/11), Bill and Melinda Gates Foundation (OPP1144149), the Helmsley Charitable Trust, and the ERC (758313). We gratefully acknowledge Ornit Hall for reading through the manuscript and for her suggestions.

# Peer review information

Kevin Pang was the primary editor of this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.

# Review history

The review history is available as Additional file 5.

# Authors’ contributions

HAE, YH, and AA conceived and designed the study, analyzed the data, and wrote the first draft of the manuscript. TB, RH, LD, and OGM gathered and analyzed data and participated in editing the manuscript. All authors had access to study data and approved the decision to submit the manuscript.

# Funding

ARC and the Sheba Medical Center support of the Sheba Microbiome Center. YH is also supported by the Israel Science Foundation (908/15), the I‑CORE program (41/11), Bill and Melinda Gates Foundation (OPP1144149), and the Helmsley Charitable Trust, and the ERC (758313).

# Availability of data and materials

Studies’ accession numbers are available in Additional file 1: table S1. Scripts used for the generation of the per‑study biom table, and code are available in the sites Github and zenodo [41, 64].

# Declarations

# Ethics approval and consent to participate

Not applicable. All meta‑analyses used publicly available de‑identified datasets.

# Consent for publication

Not applicable

# Competing interests

The authors declare no competing interests.

# Author details

1 Sheba Medical Center, Tel‑HaShomer, affiliated with the Tel‑Aviv University, Tel Aviv, Israel. 3 The Infectious Diseases Research Laboratory, Sheba Medical Center, Tel‑Hashomer, and the Department of Clinical Microbiology and Immunology, Tel Aviv University, Tel Aviv, Israel.

2 Cincinnati Children’s Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati, OH, USA.

# Received

25 October 2021

# Published online

23 February 2022

# Accepted

15 February 2022

# References

1. Braun T, et al. Individualized dynamics in the gut microbiota precede Crohn’s disease flares. Am J Gastroenterol. 2019;114(7):1142–51.
2. Gevers D, et al. The treatment‑naive microbiome in new‑onset Crohn’s disease. Cell Host Microbe. 2014;15(3):382–92.
3. Haberman Y, et al. Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature. J Clin Invest. 2014;124(8):3617–33.
4. Pittayanon R, et al. Differences in gut microbiota in patients with vs without inflammatory bowel diseases: a systematic review. Gastroenterology. 2020;158(4):930–946 e1.
5. Duvallet C, et al. Meta‑analysis of gut microbiome studies identifies disease‑specific and shared responses. Nat Commun. 2017;8(1):1784.
6. Mack I, et al. Weight gain in anorexia nervosa does not ameliorate the faecal microbiota, branched chain fatty acid profiles, and gastrointestinal complaints. Sci Rep. 2016;6:26752.
7. Zurita MF, et al. Analysis of gut microbiome, nutrition and immune status in autism spectrum disorder: a case‑control study in Ecuador. Gut Microbes. 2020;11(3):453–64.
8. Vogt NM, et al. Gut microbiome alterations in Alzheimer’s disease. Sci Rep. 2017;7(1):13537.
9. Evans SJ, et al. The gut microbiome composition associates with bipolar disorder and illness severity. J Psychiatr Res. 2017;87:23–9.
10. Giloteaux L, et al. Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome. Microbiome. 2016;4(1):30.
11. Cinek O, et al. The bacteriome at the onset of type 1 diabetes: a study from four geographically distant African and Asian countries. Diabetes Res Clin Pract. 2018;144:51–62.